Tetrabenazine for Partial Responders

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Tetrabenazine

The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS

Trial Locations (1)

M5T 1R8

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Centre for Addiction and Mental Health

OTHER

NCT00362804 - Tetrabenazine for Partial Responders | Biotech Hunter | Biotech Hunter